Loading oncology approvals…
Loading oncology approvals…
Regulatory
Every record is one authority's decision for one application or DIN, shown with its jurisdiction, date, indication text as published and status. A molecule approved in one jurisdiction for one indication is not 'approved' in general.
RegulatoryDevelopment pipeline →Methodology
Coverage
Counts of records, not of drugs approved: one application can carry several dated records (original approval, efficacy supplements, one row per DIN in Canada).
Approval records
4,342
Distinct drugs
373
Records naming a cancer
982
Dated in the last 12 months
179
| Authority | Jurisdiction | Records | Drugs | In force | Withdrawn / cancelled | Last 12 months | Latest dated record |
|---|---|---|---|---|---|---|---|
| FDA | US | 2,343 | 304 | 2,343 | 0 | 115 | Sep 18, 2026 |
| Health Canada | CA | 1,538 | 273 | 979 | 559 | 44 | Sep 22, 2026 |
| EMA | EU | 461 | 246 | 386 | 75 | 20 | Sep 18, 2026 |
Data updated 2 days agoSource updated unknown3 authority · jurisdiction pairs ingested
Feed
Latest approval date first; records without a date are listed last. Filters combine.
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Jun 18, 2013 | Letrozole | Health Canada CA | cancer not stated in this record | Marketed in Canada as ZINDA-LETROZOLE (DIN 02378213) under ATC L02BG04 LETROZOLE. Indications are not published in the Drug Product… | DIN02378213 | withdrawnsource: Dormantsince Jul 17, 2018 | health-canada-dpd |
| Jun 18, 2013 | Anastrozole | Health Canada CA | cancer not stated in this record | Marketed in Canada as ZINDA-ANASTROZOLE (DIN 02326035) under ATC L02BG03 ANASTROZOLE. Indications are not published in the Drug Product… | DIN02326035 | withdrawnsource: Dormantsince Sep 21, 2017 | health-canada-dpd |
| Jun 12, 2013 | Anastrozole | Health Canada CA | cancer not stated in this record | Marketed in Canada as AURO-ANASTROZOLE (DIN 02404990) under ATC L02BG03 ANASTROZOLE. Indications are not published in the Drug Product… | DIN02404990 | withdrawnsource: Cancelled Post Marketsince Jun 2, 2015 | health-canada-dpd |
| Jun 12, 2013 | Letrozole | Health Canada CA | cancer not stated in this record | Marketed in Canada as AURO-LETROZOLE (DIN 02404400) under ATC L02BG04 LETROZOLE. Indications are not published in the Drug Product Database… | DIN02404400 | withdrawnsource: Cancelled Post Marketsince Apr 24, 2015 | health-canada-dpd |
| Jun 12, 2013 | Cisplatin | Health Canada CA | cancer not stated in this record | Marketed in Canada as CISPLATIN INJECTION, MYLAN STD. (DIN 02396890) under ATC L01XA01 CISPLATIN. Indications are not published in the Drug… | DIN02396890 | withdrawnsource: Cancelled Post Marketsince Jul 6, 2016 | health-canada-dpd |
| Jun 11, 2013 | Topotecan | Health Canada CA | cancer not stated in this record | Marketed in Canada as TOPOTECAN HYDROCHLORIDE FOR INJECTION (DIN 02396564) under ATC L01CE01 TOPOTECAN. Indications are not published in… | DIN02396564 | withdrawnsource: Cancelled Post Marketsince Jul 6, 2016 | health-canada-dpd |
| Jun 10, 2013 | Carboplatin | Health Canada CA | cancer not stated in this record | Marketed in Canada as CARBOPLATIN INJECTION (DIN 02366053) under ATC L01XA02 CARBOPLATIN. Indications are not published in the Drug Product… | DIN02366053 | withdrawnsource: Dormantsince Jul 28, 2020 | health-canada-dpd |
| Jun 7, 2013 | Enzalutamide | Health Canada CA | cancer not stated in this record | Marketed in Canada as XTANDI (DIN 02407329) under ATC L02BB04 ENZALUTAMIDE. Indications are not published in the Drug Product Database —… | DIN02407329 | approvedsource: Marketed | health-canada-dpd |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| May 22, 2013 | Imatinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as TEVA-IMATINIB (DIN 02399814) under ATC L01EA01 IMATINIB. Indications are not published in the Drug Product Database —… | DIN02399814 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Apr 19, 2013 | Imatinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as APO-IMATINIB (DIN 02355345) under ATC L01EA01 IMATINIB. Indications are not published in the Drug Product Database —… | DIN02355345 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Mar 21, 2013 | Gemcitabine | Health Canada CA | cancer not stated in this record | Marketed in Canada as GEMCITABINE SUN FOR INJECTION (DIN 02373181) under ATC L01BC05 GEMCITABINE. Indications are not published in the Drug… | DIN |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Feb 19, 2013 | Brentuximab Vedotin | Health Canada CA | cancer not stated in this record | Marketed in Canada as ADCETRIS (DIN 02401347) under ATC L01FX05 BRENTUXIMAB VEDOTIN. Indications are not published in the Drug Product… | DIN |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Jan 15, 2013 | Anastrozole | Health Canada CA | cancer not stated in this record | Marketed in Canada as BIO-ANASTROZOLE (DIN 02392488) under ATC L02BG03 ANASTROZOLE. Indications are not published in the Drug Product… | DIN02392488 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Nov 22, 2012 | Anastrozole | Health Canada CA | cancer not stated in this record | Marketed in Canada as PRO-ANASTROZOLE (DIN 02395649) under ATC L02BG03 ANASTROZOLE. Indications are not published in the Drug Product… | DIN02395649 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Oct 26, 2012 | Anastrozole | Health Canada CA | cancer not stated in this record | Marketed in Canada as RIVA-ANASTROZOLE (DIN 02392259) under ATC L02BG03 ANASTROZOLE. Indications are not published in the Drug Product… | DIN02392259 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Sep 12, 2012 | Bendamustine | Health Canada CA | cancer not stated in this record | Marketed in Canada as TREANDA (DIN 02392569) under ATC L01AA09 BENDAMUSTINE. Indications are not published in the Drug Product Database —… | DIN02392569 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Aug 17, 2012 | Axitinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as INLYTA (DIN 02389649) under ATC L01EK01 AXITINIB. Indications are not published in the Drug Product Database — see… | DIN02389649 |
A record is one authority's decision for one application/DIN; the same molecule appears once per jurisdiction and indication. Health Canada DPD does not publish indications — its records state the brand, DIN and ATC class only, and a cancelled or dormant DIN is the status of one product, not of the molecule. FDA cancer mappings come from label text and are flagged probabilistic on the drug page.
| approvedsource: Marketed |
| health-canada-dpd |
| May 9, 2013 | Trastuzumab | Health Canada CA | cancer not stated in this record | Marketed in Canada as PERJETA-HERCEPTIN (DIN 02405024) under ATC L01FY01 PERTUZUMAB AND TRASTUZUMAB. Indications are not published in the… | DIN02405024 | approvedsource: Marketed | health-canada-dpd |
| May 9, 2013 | Pertuzumab | Health Canada CA | cancer not stated in this record | Marketed in Canada as PERJETA-HERCEPTIN (DIN 02405024) under ATC L01FY01 PERTUZUMAB AND TRASTUZUMAB. Indications are not published in the… | DIN02405024 | approvedsource: Marketed | health-canada-dpd |
| May 8, 2013 | Pertuzumab | Health Canada CA | cancer not stated in this record | Marketed in Canada as PERJETA (DIN 02405016) under ATC L01FD02 PERTUZUMAB. Indications are not published in the Drug Product Database — see… | DIN02405016 | approvedsource: Marketed | health-canada-dpd |
| May 6, 2013 | Irinotecan | Health Canada CA | cancer not stated in this record | Marketed in Canada as IRINOTECAN HYDROCHLORIDE INJECTION USP (DIN 02357585) under ATC L01CE02 IRINOTECAN. Indications are not published in… | DIN02357585 | approvedsource: Marketed | health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| Apr 19, 2013 | Imatinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as APO-IMATINIB (DIN 02355337) under ATC L01EA01 IMATINIB. Indications are not published in the Drug Product Database —… | DIN02355337 | approvedsource: Marketed | health-canada-dpd |
| Apr 2, 2013 | Regorafenib | Health Canada CA | cancer not stated in this record | Marketed in Canada as STIVARGA (DIN 02403390) under ATC L01EX05 REGORAFENIB. Indications are not published in the Drug Product Database —… | DIN02403390 | approvedsource: Marketed | health-canada-dpd |
| Apr 2, 2013 | Imatinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as TEVA-IMATINIB (DIN 02399806) under ATC L01EA01 IMATINIB. Indications are not published in the Drug Product Database —… | DIN02399806 | approvedsource: Marketed | health-canada-dpd |
| withdrawnsource: Cancelled Post Marketsince Dec 19, 2024 |
| health-canada-dpd |
| Mar 21, 2013 | Gemcitabine | Health Canada CA | cancer not stated in this record | Marketed in Canada as GEMCITABINE SUN FOR INJECTION (DIN 02373173) under ATC L01BC05 GEMCITABINE. Indications are not published in the Drug… | DIN02373173 | withdrawnsource: Cancelled Post Marketsince Dec 19, 2024 | health-canada-dpd |
| Mar 20, 2013 | Gemcitabine | Health Canada CA | cancer not stated in this record | Marketed in Canada as GEMCITABINE INJECTION (DIN 02402831) under ATC L01BC05 GEMCITABINE. Indications are not published in the Drug Product… | DIN02402831 | approvedsource: Marketed | health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| Feb 14, 2013 | Letrozole | Health Canada CA | cancer not stated in this record | Marketed in Canada as LETROZOLE (DIN 02402025) under ATC L02BG04 LETROZOLE. Indications are not published in the Drug Product Database —… | DIN02402025 | approvedsource: Marketed | health-canada-dpd |
| Feb 14, 2013 | Methotrexate | Health Canada CA | cancer not stated in this record | Marketed in Canada as METHOTREXATE INJECTION USP (DIN 02398427) under ATC L01BA01 METHOTREXATE. Indications are not published in the Drug… | DIN02398427 | withdrawnsource: Cancelled Post Marketsince Jul 28, 2023 | health-canada-dpd |
| Feb 12, 2013 | Letrozole | Health Canada CA | cancer not stated in this record | Marketed in Canada as BIO-LETROZOLE (DIN 02392496) under ATC L02BG04 LETROZOLE. Indications are not published in the Drug Product Database… | DIN02392496 | approvedsource: Marketed | health-canada-dpd |
| Feb 8, 2013 | Vinblastine | Health Canada CA | cancer not stated in this record | Marketed in Canada as VINBLASTINE SULPHATE INJECTION (DIN 02401460) under ATC L01CA01 VINBLASTINE. Indications are not published in the… | DIN02401460 | approvedsource: Marketed | health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| Jan 8, 2013 | Letrozole | Health Canada CA | cancer not stated in this record | Marketed in Canada as MAR-LETROZOLE (DIN 02373424) under ATC L02BG04 LETROZOLE. Indications are not published in the Drug Product Database… | DIN02373424 | approvedsource: Marketed | health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| Nov 7, 2012 | Temozolomide | Health Canada CA | cancer not stated in this record | Marketed in Canada as TEVA-TEMOZOLOMIDE (DIN 02395312) under ATC L01AX03 TEMOZOLOMIDE. Indications are not published in the Drug Product… | DIN02395312 | approvedsource: Marketed | health-canada-dpd |
| Nov 7, 2012 | Temozolomide | Health Canada CA | cancer not stated in this record | Marketed in Canada as TEVA-TEMOZOLOMIDE (DIN 02395290) under ATC L01AX03 TEMOZOLOMIDE. Indications are not published in the Drug Product… | DIN02395290 | approvedsource: Marketed | health-canada-dpd |
| Nov 7, 2012 | Temozolomide | Health Canada CA | cancer not stated in this record | Marketed in Canada as TEVA-TEMOZOLOMIDE (DIN 02395282) under ATC L01AX03 TEMOZOLOMIDE. Indications are not published in the Drug Product… | DIN02395282 | approvedsource: Marketed | health-canada-dpd |
| Nov 7, 2012 | Temozolomide | Health Canada CA | cancer not stated in this record | Marketed in Canada as TEVA-TEMOZOLOMIDE (DIN 02395274) under ATC L01AX03 TEMOZOLOMIDE. Indications are not published in the Drug Product… | DIN02395274 | approvedsource: Marketed | health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| Oct 25, 2012 | Anastrozole | Health Canada CA | cancer not stated in this record | Marketed in Canada as TEVA-ANASTROZOLE (DIN 02394898) under ATC L02BG03 ANASTROZOLE. Indications are not published in the Drug Product… | DIN02394898 | approvedsource: Marketed | health-canada-dpd |
| Oct 25, 2012 | Anastrozole | Health Canada CA | cancer not stated in this record | Marketed in Canada as MINT-ANASTROZOLE (DIN 02393573) under ATC L02BG03 ANASTROZOLE. Indications are not published in the Drug Product… | DIN02393573 | approvedsource: Marketed | health-canada-dpd |
| Oct 25, 2012 | Anastrozole | Health Canada CA | cancer not stated in this record | Marketed in Canada as MAR-ANASTROZOLE (DIN 02379562) under ATC L02BG03 ANASTROZOLE. Indications are not published in the Drug Product… | DIN02379562 | approvedsource: Marketed | health-canada-dpd |
| Oct 25, 2012 | Anastrozole | Health Canada CA | cancer not stated in this record | Marketed in Canada as MED-ANASTROZOLE (DIN 02379104) under ATC L02BG03 ANASTROZOLE. Indications are not published in the Drug Product… | DIN02379104 | withdrawnsource: Dormantsince Mar 23, 2018 | health-canada-dpd |
| Oct 25, 2012 | Anastrozole | Health Canada CA | cancer not stated in this record | Marketed in Canada as APO-ANASTROZOLE (DIN 02374420) under ATC L02BG03 ANASTROZOLE. Indications are not published in the Drug Product… | DIN02374420 | approvedsource: Marketed | health-canada-dpd |
| Oct 25, 2012 | Anastrozole | Health Canada CA | cancer not stated in this record | Marketed in Canada as TARO-ANASTROZOLE (DIN 02365650) under ATC L02BG03 ANASTROZOLE. Indications are not published in the Drug Product… | DIN02365650 | approvedsource: Marketed | health-canada-dpd |
| Oct 25, 2012 | Anastrozole | Health Canada CA | cancer not stated in this record | Marketed in Canada as MYLAN-ANASTROZOLE (DIN 02361418) under ATC L02BG03 ANASTROZOLE. Indications are not published in the Drug Product… | DIN02361418 | withdrawnsource: Cancelled Post Marketsince Jan 9, 2017 | health-canada-dpd |
| Oct 25, 2012 | Anastrozole | Health Canada CA | cancer not stated in this record | Marketed in Canada as ACH-ANASTROZOLE (DIN 02351218) under ATC L02BG03 ANASTROZOLE. Indications are not published in the Drug Product… | DIN02351218 | approvedsource: Marketed | health-canada-dpd |
| Oct 25, 2012 | Anastrozole | Health Canada CA | cancer not stated in this record | Marketed in Canada as JAMP-ANASTROZOLE (DIN 02339080) under ATC L02BG03 ANASTROZOLE. Indications are not published in the Drug Product… | DIN02339080 | approvedsource: Marketed | health-canada-dpd |
| Oct 25, 2012 | Anastrozole | Health Canada CA | cancer not stated in this record | Marketed in Canada as RAN-ANASTROZOLE (DIN 02328690) under ATC L02BG03 ANASTROZOLE. Indications are not published in the Drug Product… | DIN02328690 | withdrawnsource: Cancelled Post Marketsince Jan 22, 2024 | health-canada-dpd |
| Oct 25, 2012 | Anastrozole | Health Canada CA | cancer not stated in this record | Marketed in Canada as PMS-ANASTROZOLE (DIN 02320738) under ATC L02BG03 ANASTROZOLE. Indications are not published in the Drug Product… | DIN02320738 | approvedsource: Marketed | health-canada-dpd |
| Oct 25, 2012 | Anastrozole | Health Canada CA | cancer not stated in this record | Marketed in Canada as TEVA-ANASTROZOLE (DIN 02313049) under ATC L02BG03 ANASTROZOLE. Indications are not published in the Drug Product… | DIN02313049 | withdrawnsource: Cancelled Post Marketsince Jun 11, 2018 | health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| Sep 12, 2012 | Bendamustine | Health Canada CA | cancer not stated in this record | Marketed in Canada as TREANDA (DIN 02392550) under ATC L01AA09 BENDAMUSTINE. Indications are not published in the Drug Product Database —… | DIN02392550 | approvedsource: Marketed | health-canada-dpd |
| Sep 7, 2012 | Bicalutamide | Health Canada CA | cancer not stated in this record | Marketed in Canada as RAN-BICALUTAMIDE (DIN 02371324) under ATC L02BB03 BICALUTAMIDE. Indications are not published in the Drug Product… | DIN02371324 | withdrawnsource: Cancelled Post Marketsince Aug 23, 2022 | health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| Aug 17, 2012 | Axitinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as INLYTA (DIN 02389630) under ATC L01EK01 AXITINIB. Indications are not published in the Drug Product Database — see… | DIN02389630 | approvedsource: Marketed | health-canada-dpd |